Rationale: Auditory verbal hallucinations (AVH) - hearing voices that others cannot hear - are common in mental illnesses. For many people AVH are distressing, disabling and persistent, despite medication. Current psychological interventions show low to medium effects. Preliminary studies suggest that an innovative empowering psychological therapy using computer simulations representing the AVH (avatars) can be effective for reducing AVH distress and frequency. Virtual reality (VR) has the potential to improve this treatment. Therefore, we developed a novel VR treatment for this problem. In this study, the effect of this treatment will be investigated. Objective: To test the effect of a novel VR treatment for AVH (VR-VOICES) on distress and frequency of AVH in patients with a psychiatric disorder. Furthermore, to investigate the effect of VR-VOICES on clinical symptoms, quality of life, and healthcare costs of the treatment.
Study design: Single-blind randomized controlled intervention trial (RCT) with two arms: VR-VOICES as intervention and treatment as usual (TAU) as a control condition. Study population: Patients with a DSM-5 diagnosis who have experienced distressing AVH for at least 3 months, who are 16 years or older (N=112). Intervention: * VR-VOICES intervention: 7-10 sessions of 45-60 minutes of individual VR assisted therapy and two booster sessions, in addition to TAU. Participants allocated to VR-VOICES create together with their therapist a VR digital representation (avatar with face, body and voice) of the voice that bothers them most. Patients have dialogues with the avatar, voiced by the therapist. As indicated in the treatment protocol, over the sessions the avatar will become less hostile and the participant will gain more power and resilience over the avatar. * Control: TAU as described in the current Dutch treatment guidelines, which generally exists of pharmacological treatment, supportive counseling, and psychological interventions such as CBT and coping strategies. Main study parameters/endpoints: Assessments will be obtained at baseline, within some VR-VOICES sessions, posttreatment (12 weeks after baseline), and at 6-month follow-up. Primary outcome: severity of AVH (total score on the auditory hallucinations scale of the PSYRATS) at post-treatment. Secondary outcomes: in-depth characteristics of AVH such as the frequency, voice impact, beliefs about voices, power relative to voices, levels of anxiety, distress and impact on daily life as measured with questionnaires and diary assessments in the flow of daily life. Other secondary outcomes include clinical symptoms, cost-effectiveness and quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
112
7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
Treatment as usual as provided by the mental health centers
Lentis
Groningen, Provincie Groningen, Netherlands
NOT_YET_RECRUITINGGGZ Drenthe
Assen, Netherlands
RECRUITINGUniversity Medical Center Groningen
Groningen, Netherlands
RECRUITINGVoices severity
The Psychotic Symptoms Rating Scales (PSYRATS) is a semi-structured interview to assess characteristics of hallucinations and delusions. The auditory hallucinations subscale (AHS), which is used as the primary outcome, has 11 items.
Time frame: Between baseline and posttreatment after 3 months
Voice severity (frequency and distress) and delusions
The Psychotic Symptoms Rating Scales (PSYRATS) is a semi-structured interview to assess characteristics of hallucinations and delusions. The auditory hallucinations subscale (AHS) has 11 items.The delusions subscale (DS) has six items.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Beliefs about voice power, voice intent and responding styles (Beliefs about Voices Questionnaire-Revised, BAVQ-R)
The BAVQ-R has 54 items, measured on a four-point scale: "disagree" (0), "unsure" (1), "slightly agree" (2), "strongly agree"(3).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Social comparison with voices (Social Comparison Rating Scale To Voices, SCRS)
The SCRS has 11 items measuring characteristics of the participants as compared to their voices on a 10-point likert scale ranging from 1-10.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Impact of voice-hearing (Voice Impact Scale, VIS)
The VIS has 24 items measured on a 10-point likert scale ranging from 1 (totally disagree) to 10 (totally agree).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Voices acceptance (Voices Acceptance and Action scale, VAAS)
Section A of the VAAS has 12 items and section B 27. Items are rated on a 5-point scale: strongly disagree, disagree, unsure or neutral, or strongly agree.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Depressive symptoms (Inventory of Depressive Symptomatology, IDS)
The IDS-SR is a 30-item questionnaire. Each item has four statements that reflect various degrees of symptom severity, scored on a four-point scale from 0 to 3.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Paranoid ideation (Revised Green Paranoid Thoughts Scale, R-GPTS)
The R-GPTS part A consists of 8 items, and B of 10 items. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (totally).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Self-esteem (Self Esteem Rating Scale, SERS)
The SERS has 20 items which are rated on a 7-point likert scale from 1 (strongly disagree) -7 (strongly agree).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Health care costs (Treatment Inventory of Costs in Patients with psychiatric disorders, TIC-P)
The TiC-P is a self-report questionnaire that consists of two parts. The first part includes 38 structured questions, starting with yes/no questions and followed by a question on the volume of medical consumption.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Costs production losses (Treatment Inventory of Costs in Patients with psychiatric disorders, TIC-P)
The TiC-P is a self-report questionnaire that consists of two parts. The second part deals with 12 questions about work to collect data on productivity losses due to health problems.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Quality of life (Sheehan Disability Scale, SDS)
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life on a scale from 0-10, and assess how many days someone missed work/school/responsibilities and how many days someone was unproductive.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Quality of life (EuroQol, EQ-5D-5L)
The first 25 items of this questionnaires are based on five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The patient is asked to indicate their health status by choosing the most appropriate level: no problems, slight problems, moderate problems, severe problems, and extreme problems. The last question indicates their current health status on a scale from 0 to 100.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Empowerment/self-efficacy (Mental Health Confidence Scale, MHCS)
The MHCS has 16 items that are measured on a 6-point likert scale ranging from totally not confidant
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Experience sampling method (ESM) of auditory hallucinations and mental states
ESM of auditory verbal hallucinations and mental states measured in the flow of daily life. ESM is a structured diary method for reporting momentary experiences 18. Individuals complete short questionnaires on their mobile device, by pressing a link in a text message. Participants will complete ESM 5x daily for 7 days, completion takes ±1 minute. Participants have to complete the questionnaire within 30 minutes after the text message notification, the interval between measurements is 3 hours.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.